

CONFLICT-OF-INTEREST STATEMENT

Name of Journal: World Journal of Virology

ESPS Manuscript NO: 18645

Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?

Tatsuo Kanda, Shingo Nakamoto, Osamu Yokosuka

Conflict-of-interest statement: Tatsuo Kanda reports receiving lecture fees from Chugai Pharmaceutical, MSD, Tanabe-Mitsubishi, Ajinomoto, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen Pharmaceutical and GlaxoSmithKline, and Osamu Yokosuka reports receiving grant support from Chugai Pharmaceutical, Bayer, MSD, Daiichi-Sankyo, Tanabe-Mitsubishi, Bristol-Myers Squibb, Gilead Sciences and Taiho Pharmaceutical. Shingo Nakamoto has no conflict of interest to declare.

Signature: Tatsuo Kanda **Date:** 6/25/2015